The evolving data now show clear biological efficacy with impact on hard clinical outcomes, says Sahil Parikh.

Cordis announced that its Selution SLR Sustane percutaneous transluminal angioplasty (PTA) sirolimus drug-eluting balloon ...

Sirolimus-eluting stents reduce rates of restenosis and reintervention, as compared with uncoated stents. Data are limited regarding the safety and efficacy of such stents in primary percutaneous ...

REVA Medical, LLC today announced the successful completion of a live case demonstration featuring the MOTIV® sirolimus-eluting bioresorbable vascular scaffold and the presentation of late-breaking ...

Cardiac rhabdomyoma is the most common fetal cardiac tumor. 1 We report a case of progressively obstructive fetal cardiac rhabdomyomas with regression in utero during treatment of the mother with an ...

Please provide your email address to receive an email when new articles are posted on . Four of six patients who used sirolimus had positive responses and discontinued systemic corticosteroids. Three ...

Results from the first randomized clinical trial in the United States to compare a sirolimus-eluting balloon (DEB) to a control group consisting of drug-eluting stent (DES) and balloon angioplasty (BA ...

BETHESDA, Md., Aug. 30, 2022 /PRNewswire/ -- Nobelpharma America, LLC, a pharmaceutical and medical device company headquartered in Bethesda, Maryland, and a subsidiary of Nobelpharma Co., Ltd. in ...

NEW ORLEANS — A balloon angioplasty device coated with sirolimus yielded significant reductions in major adverse events, including limb amputation, in the first phase 3 trial to associate any balloon ...

Graft-vs-host disease (GVHD) remains the most significant cause of morbidity and mortality after allogeneic stem cell transplantation. Despite this, the combination of a calcineurin inhibitor with ...